0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Study |

Finasteride Treatment of Female Pattern Hair Loss FREE

Matilde Iorizzo, MD; Colombina Vincenzi, MD; Stylianos Voudouris, MD; Bianca Maria Piraccini, MD, PhD; Antonella Tosti, MD
[+] Author Affiliations

Author Affiliations: Department of Dermatology, University of Bologna, Bologna, Italy.


Arch Dermatol. 2006;142(3):298-302. doi:10.1001/archderm.142.3.298.
Text Size: A A A
Published online

Objective  To evaluate the efficacy of oral finasteride therapy associated with an oral contraceptive containing drospirenone and ethinyl estradiol in premenopausal women with female pattern hair loss.

Setting  Outpatient consultation for hair disorders at the Department of Dermatology, University of Bologna.

Patients and Intervention  Thirty-seven women with female pattern hair loss were treated with oral finasteride, 2.5 mg/d, while taking an oral contraceptive containing drospirenone and ethinyl estradiol. Treatment efficacy was evaluated using global photography and the hair density score from videodermoscopy. A self-administered questionnaire was used to assess patient evaluation of treatment effectiveness.

Results  At 12-month follow-up, 23 of the 37 patients were rated as improved using global photography (12 were slightly improved, 8 were moderately improved, and 3 were greatly improved). No improvement was recorded in 13 patients. One patient experienced worsening of the condition. There was a statistically significant (P = .002) increase in the hair density score in 12 patients. No adverse reactions to the drug were reported.

Conclusions  Sixty-two percent of the patients demonstrated some improvement of their hair loss with the use of finasteride, 2.5 mg/d, while taking the oral contraceptive. It is unclear whether the success was due to a higher dosage of finasteride (2.5 mg instead of 1 mg) or to its association with the oral contraceptive containing drospirenone, which has an antiandrogenic effect. Further studies are necessary to understand which patterns of female pattern hair loss respond better to this treatment.

Figures in this Article

Female pattern hair loss (FPHL), the most common form of hair loss, affects up to 50% of women during their life.1 Although hair thinning in women with FPHL may be diffuse, 3 different clinical patterns have been described: the Christmas tree pattern,2 the Ludwig pattern,3 and the Hamilton pattern.4 Patients who experience hair thinning complain of social anxiety and embarrassment. If left untreated, FPHL may be rapidly progressive.

Treatment for FPHL consists mainly of topical minoxidil, which is effective5 but sometimes is not well accepted by the patient. The efficacy of oral antiandrogens is not well established. Although cyproterone acetate is prescribed in Europe to treat FPHL,68 its efficacy is still controversial. A controlled 12-month randomized trial9 compared the effects of cyproterone acetate, 52 mg/d, with 2% topical minoxidil in FPHL. All the patients took oral contraceptives. After 6 months of treatment, minoxidil was effective in women with a low body mass index and the absence of hyperandrogenism. Cyproterone was effective when other signs of hyperandrogenism were present and when body mass index was high.

In a recent study,10 treatment with oral antiandrogens (spironolactone and cyproterone and oral contraceptives in premenopausal women) produced hair regrowth in 35 (44%) of 80 women with FPHL. This study showed no relationship between response to treatment and patient age, menopausal status, and serum hormone levels. Spironolactone (100-200 mg/d) and cyproterone acetate (50-100 mg/d) produced similar results. In a small 12-month randomized trial,11 flutamide was reported to be effective at 250 mg/d and was better than cyproterone acetate, 50 mg/d, and finasteride, 5 mg/d. We report herein our experience with finasteride, 2.5 mg/d, taken with an oral contraceptive containing drospirenone and ethinyl estradiol in 37 premenopausal women with FPHL.

STUDY PATIENTS AND DESIGN

Thirty-seven premenopausal women with FPHL seen for consultation regarding hair loss were enrolled in this study (Table 1). The thinning hair was not associated with increased shedding, and the pull test result was negative. Other inclusion criteria were normal androgen levels and ovulatory cycles, normal iron and ferritin levels, and negative thyroid function test results. Patients affected by acne or hirsutism were excluded.

Table Graphic Jump LocationTable 1. Characteristics of 37 Women With Female Pattern Hair Loss

After providing informed consent, patients were prescribed finasteride, 2.5 mg/d, and an oral contraceptive containing drospirenone, 3 mg, and ethinyl estradiol, 30 μg (Yasmin; Schering AG Germany, Berlin, Germany). All 37 women had refused to apply topical minoxidil. Camacho12 reported good results with this finasteride dose in patients with FPHL. Finasteride treatment, which is teratogenic, requires oral contraception to prevent pregnancy. Ethinyl estradiol–drospirenone, which has antiandrogenic activity, was selected because of its possible adjuvant effect on FPHL.

EVALUATION PROCEDURES

Global photography, using a Nikon-Canfield D1 camera with a Nikon 60-mm f2.8 lens (Nikon Inc, Melville, NY), was performed at baseline and after 12 months of treatment. The patient's head was placed in a stereotactic device to ensure consistent positioning and photographic distance. Pictures obtained at 12 months were compared with those obtained at baseline and rated by one of us (M.I.), who was not involved in the clinical study. A 7-point scale was used to evaluate hair density in response to treatment13: −3, greatly decreased; −2, moderately decreased; −1, slightly decreased; 0, no change; 1, slightly increased; 2, moderately increased; and 3, greatly increased.

Hair density score at baseline and after 12 months was evaluated using computerized light videodermoscopy (FotoFinder dermoscope; Teachscreen Software GmbH, Bad Birnbach, Germany) with ×20 magnification lenses. Probed images were digitized and stored. To assess the hair density score, we adapted the scale proposed by de Lacharrière et al14 to our instrument. The reference scores for hair density were obtained by counting the number of hairs on 1 side from center parting within the same area at the vertex (cross between nose line and ear implantation): 1, baldness (<15 hairs); 2, very low hair density (15-20 hairs); 3, low hair density (21-30 hairs); 4, medium hair density (31-40 hairs); 5, high hair density (41-50 hairs); and 6, very high hair density (>50 hairs).

One of us (C.V.) showed the patients their photographs at baseline and at 12 months and requested that they assess the results of treatment using a self-administered questionnaire. They were questioned about their satisfaction, the appearance of their hair, the stabilization of hair loss, and the promotion of hair growth using the 7-point scale described previously herein.

STATISTICAL ANALYSIS

A t test for matched samples was run on hair density values to corroborate the qualitative findings.

The patients ranged in age from 19 to 50 years (mean, 33.7 years) (Table 1). After 12 months, 23 of the 37 patients were rated as improved using global photography (12 were slightly improved, 8 were moderately improved [Figure 1], and 3 were greatly improved [Figure 2]). No improvement was recorded in 13 patients. One patient experienced worsening of the condition despite treatment. Hair density scores increased in 12 patients (Figure 3) from a mean density of 4.5 at baseline to 4.8 at 12 months (t = −3.375; P = .002). Using the self-administered questionnaire, 29 patients judged their condition as improved and 8 as stabilized. None of the women considered their condition worsened (Table 2). No patients experienced adverse reactions during treatment.

Place holder to copy figure label and caption
Figure 1.

Christmas tree pattern of hair loss shows moderate improvement compared with baseline (A) after 12 months of oral finasteride treatment (B).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Ludwig pattern of hair loss shows great improvement compared with baseline (A) after 12 months of oral finasteride treatment (B).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.

Improvement in the hair density score compared with baseline (A) at 12 months of oral finasteride treatment (B).

Graphic Jump Location
Table Graphic Jump LocationTable 2. Patient and Investigator Assessments of FPHL After 12 Months of Treatment*

Finasteride is a 5α-reductase type II inhibitor currently approved to treat male androgenetic alopecia at a dosage of 1 mg/d. Because of the potential risk of teratogenicity in a male fetus,15 finasteride is contraindicated in women of childbearing potential. The efficacy of finasteride in FPHL is still controversial.

A multicenter, double-blind, placebo-controlled, randomized study16 of finasteride, 1 mg/d, in postmenopausal women with FPHL showed negative results in increasing hair growth and slowing the progression of hair thinning. After 12 months of treatment, patients in the finasteride and placebo groups had a modest decrease in hair count from baseline. Scalp biopsies also revealed no differences in the anagen-telogen ratio and the terminal hair–miniaturized hair ratio. In this study, the lack of efficacy of finasteride may have been related to the older age of the patients. Hair thinning may not be androgen dependent in senescent scalps. Moreover, in this study with negative findings, finasteride was administered at a dosage of 1 mg/d, which might be inadequate for FPHL.

Recently, noncontrolled studies12,1719 indicated that finasteride therapy can be effective in premenopausal and postmenopausal women with and without signs of hyperandrogenism. Camacho12 reported hair regrowth using finasteride, 2.5 mg/d, in 41 women with FPHL and SAHA (seborrhea, acne, hirsutism, and alopecia) syndrome. Thai and Sinclair17 administered finasteride at a dosage of 5 mg/wk (<1 mg/d) to a 67-year-old postmenopausal woman without signs of hyperandrogenism and with Ludwig FPHL. After 12 months of treatment the patient showed a significant increase in hair density. Shum et al18 administered finasteride to 4 women with hyperandrogenism at a dosage of 1.25 mg/d. Two of these patients had a Ludwig-type FPHL, and the other 2 had a Hamilton pattern. Only 2 of the women were postmenopausal, but the others had a history of infertility with irregular menses. Increased hair growth and decreased progression of hair loss were observed in all the patients after 6 months and 1, 2, and 2.5 years of treatment, respectively. The efficacy of finasteride in postmenopausal normoandrogenic women with FPHL was reported by Trueb19 as early as after 6 months of treatment. Finasteride was administered at 2.5 mg/d in 4 women, 1 with the Christmas tree pattern and 3 with the Ludwig pattern, and finasteride, 5 mg/d, in 1 woman with the Hamilton pattern.

A recent case report20 also indicated that the dual 5α-reductase inhibitor dutasteride, 0.5 mg/d, can improve FPHL. All these studies of oral antiandrogens in premenopausal women with FPHL used oral contraception to prevent pregnancy. However, different contraceptives were used, and information about a possible effect of these agents on treatment efficacy is lacking.

In the present study, 62% of patients demonstrated some improvement of their hair loss after 1 year of treatment with finasteride, 2.5 mg/d, taken with an oral contraceptive containing drospirenone and ethinyl estradiol (32% slightly improved, 22% moderately improved, and 8% greatly improved). Finasteride was well tolerated compared with the other oral antiandrogens, and none of the patients reported adverse effects. This treatment was well accepted by the patients, who judged the results to be even better than did the investigators. The patient's opinion being generally more optimistic than that of the investigator is not surprising. In double- blind clinical trials on the efficacy of finasteride on male androgenetic alopecia,13 patients treated with placebo reported improvement of their condition.

The efficacy of finasteride in two thirds of our premenopausal women may be due to the higher dosage used. The contraceptive contains drospirenone, a progestin analog of spironolactone. It is possible that even at a very low dosage (3 mg), drospirenone might have had an additional effect in promoting hair growth. Owing to its antiandrogenic and diuretic activities, this pill may be useful for FPHL, but it is also well accepted because it provides weight stability or even loss.21 The potential risk of teratogenicity of finasteride in women with childbearing potential requires oral contraception. We used the same contraception in all the patients to avoid the confounding role of contraceptive pills containing progestins with possible androgenic activity.

Although our study is not randomized, blinded, and placebo controlled and does not include scalp biopsies, the clinical results using global photography, hair density scores, and patient self-assessment provide a basis for future work. Further studies are needed to establish the optimal dosage and mode of administration of finasteride in premenopausal women and to definitively assess the efficacy of this drug compared with oral antiandrogens.

Correspondence: Antonella Tosti, MD, Department of Dermatology, University of Bologna, Via Massarenti, 1-40138 Bologna, Italy (tosti@med.unibo.it).

Financial Disclosure: None.

Accepted for Publication: November 1, 2005.

Author Contributions:Study concept and design: Iorizzo and Tosti. Acquisition of data: Voudouris. Analysis and interpretation of data: Iorizzo, Vincenzi, and Tosti. Drafting of the manuscript: Iorizzo, Piraccini, and Tosti. Critical revision of the manuscript for important intellectual content: Iorizzo and Tosti. Study supervision: Iorizzo and Tosti.

Acknowledgment: We thank Gabriella Fabbrocini, MD, University of Naples (Naples, Italy), for statistical analysis.

Price  VH Androgenetic alopecia in women. J Investig Dermatol Symp Proc 2003;824- 27
PubMed Link to Article
Olsen  EA Female pattern hair loss. J Am Acad Dermatol 2001;45S70- S80
PubMed Link to Article
Ludwig  E Classification of the types of androgenetic alopecia (common baldness) occurring in female sex. Br J Dermatol 1977;97247- 254
PubMed Link to Article
Venning  VADawber  RP Patterned androgenetic alopecia in women. J Am Acad Dermatol 1988;181073- 1077
PubMed Link to Article
Price  VHMenefee  E Quantitative estimation of hair growth, I: androgenetic alopecia in women: effect of minoxidil. J Invest Dermatol 1990;95683- 687
PubMed Link to Article
Dawber  RPRSonnex  TRalfs  I Oral antiandrogen treatment of common baldness in women [abstract]. Br J Dermatol 1982;107 ((suppl 22)) 20
Link to Article
Mortimer  CHRushton  HJames  KC Effective medical treatment of common baldness in women. Clin Exp Dermatol 1984;9342- 350
PubMed Link to Article
Peereboom-Wynia  JDvan der Willigen  AHvan Joost  TStolz  E The effect of cyproterone acetate on hair roots and hair shafts diameter in androgenetic alopecia in females. Acta Derm Venereol 1989;69395- 398
PubMed
Vexiau  PChaspoux  CBoudou  P  et al.  Effects of minoxidil 2% vs cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol 2002;146992- 999
PubMed Link to Article
Sinclair  RWewerinke  MJolley  D Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol 2005;152466- 473
PubMed Link to Article
Carmina  ELobo  RA Treatment of hyperandrogenic alopecia in women. Fertil Steril 2003;7991- 95
PubMed Link to Article
Camacho  F Hirsutismo: enfoque clinico terapéutico. Act Terap Dermatol 2001;24190- 206
Kaufman  KDOlsen  EAWhiting  D  et al.  Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol 1998;39578- 588
PubMed Link to Article
de Lacharrière  ODeloche  CMisciali  C  et al.  Hair diameter diversity. Arch Dermatol 2001;137641- 646
PubMed
Prahalada  STarantal  ASHarris  GS  et al.  Effects of finasteride, a type 2 5α-reductase inhibitor, on fetal development in the rhesus monkey (Macaca mulatta). Teratology 1997;55119- 131
PubMed Link to Article
Price  VHRoberts  JLHordinsky  M  et al.  Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 2000;43768- 776
PubMed Link to Article
Thai  KESinclair  R Finasteride for female androgenetic alopecia. Br J Dermatol 2002;147812- 813
PubMed Link to Article
Shum  KWCullen  DRMessenger  AG Hair loss in women with hyperandrogenism: four cases responding to finasteride. J Am Acad Dermatol 2002;47733- 739
PubMed Link to Article
Trueb  RM Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology 2004;209202- 207
PubMed Link to Article
Olszewska  MRudnicka  L Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol 2005;4637- 640
PubMed
Batur  PElder  JMayer  M Update on contraception: benefits and risks of the new formulations. Cleve Clin J Med 2003;70681- 696
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure 1.

Christmas tree pattern of hair loss shows moderate improvement compared with baseline (A) after 12 months of oral finasteride treatment (B).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Ludwig pattern of hair loss shows great improvement compared with baseline (A) after 12 months of oral finasteride treatment (B).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.

Improvement in the hair density score compared with baseline (A) at 12 months of oral finasteride treatment (B).

Graphic Jump Location

Tables

Table Graphic Jump LocationTable 1. Characteristics of 37 Women With Female Pattern Hair Loss
Table Graphic Jump LocationTable 2. Patient and Investigator Assessments of FPHL After 12 Months of Treatment*

References

Price  VH Androgenetic alopecia in women. J Investig Dermatol Symp Proc 2003;824- 27
PubMed Link to Article
Olsen  EA Female pattern hair loss. J Am Acad Dermatol 2001;45S70- S80
PubMed Link to Article
Ludwig  E Classification of the types of androgenetic alopecia (common baldness) occurring in female sex. Br J Dermatol 1977;97247- 254
PubMed Link to Article
Venning  VADawber  RP Patterned androgenetic alopecia in women. J Am Acad Dermatol 1988;181073- 1077
PubMed Link to Article
Price  VHMenefee  E Quantitative estimation of hair growth, I: androgenetic alopecia in women: effect of minoxidil. J Invest Dermatol 1990;95683- 687
PubMed Link to Article
Dawber  RPRSonnex  TRalfs  I Oral antiandrogen treatment of common baldness in women [abstract]. Br J Dermatol 1982;107 ((suppl 22)) 20
Link to Article
Mortimer  CHRushton  HJames  KC Effective medical treatment of common baldness in women. Clin Exp Dermatol 1984;9342- 350
PubMed Link to Article
Peereboom-Wynia  JDvan der Willigen  AHvan Joost  TStolz  E The effect of cyproterone acetate on hair roots and hair shafts diameter in androgenetic alopecia in females. Acta Derm Venereol 1989;69395- 398
PubMed
Vexiau  PChaspoux  CBoudou  P  et al.  Effects of minoxidil 2% vs cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol 2002;146992- 999
PubMed Link to Article
Sinclair  RWewerinke  MJolley  D Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol 2005;152466- 473
PubMed Link to Article
Carmina  ELobo  RA Treatment of hyperandrogenic alopecia in women. Fertil Steril 2003;7991- 95
PubMed Link to Article
Camacho  F Hirsutismo: enfoque clinico terapéutico. Act Terap Dermatol 2001;24190- 206
Kaufman  KDOlsen  EAWhiting  D  et al.  Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol 1998;39578- 588
PubMed Link to Article
de Lacharrière  ODeloche  CMisciali  C  et al.  Hair diameter diversity. Arch Dermatol 2001;137641- 646
PubMed
Prahalada  STarantal  ASHarris  GS  et al.  Effects of finasteride, a type 2 5α-reductase inhibitor, on fetal development in the rhesus monkey (Macaca mulatta). Teratology 1997;55119- 131
PubMed Link to Article
Price  VHRoberts  JLHordinsky  M  et al.  Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 2000;43768- 776
PubMed Link to Article
Thai  KESinclair  R Finasteride for female androgenetic alopecia. Br J Dermatol 2002;147812- 813
PubMed Link to Article
Shum  KWCullen  DRMessenger  AG Hair loss in women with hyperandrogenism: four cases responding to finasteride. J Am Acad Dermatol 2002;47733- 739
PubMed Link to Article
Trueb  RM Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology 2004;209202- 207
PubMed Link to Article
Olszewska  MRudnicka  L Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol 2005;4637- 640
PubMed
Batur  PElder  JMayer  M Update on contraception: benefits and risks of the new formulations. Cleve Clin J Med 2003;70681- 696
PubMed Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 28

Related Content

Customize your page view by dragging & repositioning the boxes below.